{"gene":"PRKAR1B","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2014,"finding":"The PRKAR1B p.Leu50Arg (L50R) missense mutation causes reduced binding of the R1β regulatory subunit to both A-kinase anchoring proteins (AKAPs) and the catalytic subunit of PKA, leading to subcellular dislocalization of the catalytic subunit and hyperphosphorylation of intermediate filaments. Mutant PRKAR1B accumulates specifically in neuronal inclusions.","method":"Proteomics, biochemical assay, linkage analysis/exome sequencing, immunohistochemistry of patient brain tissue","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2-3 — patient tissue proteomics and biochemical pattern, single lab, no in vitro reconstitution of binding","pmids":["24722252"],"is_preprint":false},{"year":2021,"finding":"De novo missense variants in PRKAR1B (including p.Arg335Trp) alter basal PKA activity in transfected cells, establishing that PRKAR1B variants cause a neurodevelopmental disorder through dysregulated PKA signaling.","method":"In vitro PKA activity assay in cells transfected with variant-harboring PRKAR1B expression constructs; exome sequencing for variant identification","journal":"Genetics in medicine : official journal of the American College of Medical Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro functional assay with multiple variants, single lab","pmids":["33833410"],"is_preprint":false},{"year":2020,"finding":"PRKAR1B variants p.A67V and p.A300T decrease basal PKA activity in vitro, and the mutant R1β subunits bind the PKA catalytic subunit Cα more strongly than wildtype as measured by FRET in co-transfected HEK293 cells. Copy-number gains of PRKAR1B in cortisol-producing adrenal adenomas are associated with increased PRKAR1B mRNA and reduced PKA activity.","method":"In vitro PKA activity assay; FRET in co-transfected HEK293 cells; copy-number variant analysis with mRNA quantification","journal":"Genetics in medicine : official journal of the American College of Medical Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — FRET and enzymatic assay, two orthogonal methods, single lab","pmids":["32895490"],"is_preprint":false},{"year":2024,"finding":"The RIβ-L50R mutation disrupts RIβ homodimerization, causing aggregation of RIβ monomers in an age-dependent manner. Interaction with the catalytic subunit protects RIβ-L50R from self-aggregation in a dose-dependent manner. cAMP signaling induces RIβ-L50R aggregation. These mechanisms were demonstrated in a knock-in mouse model, live cell cultures, and post-mortem human brains.","method":"Biochemical assays (dimerization, aggregation), immunohistochemistry, behavioral assessments in knock-in mouse model, cell culture experiments","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (biochemical, in vivo mouse model, human tissue), mechanistic dissection of dimerization and aggregation","pmids":["38743596"],"is_preprint":false},{"year":2025,"finding":"Structural analysis and circular dichroism spectroscopy showed that cellular protein aggregation of RIβ-L50R results from misfolded RIβ subunits that prevent holoenzyme assembly and AKAP anchoring. The RIβ-L50R:C heterodimer maintains high affinity to the catalytic subunit but exhibits reduced cooperativity, requiring lower cAMP concentrations for dissociation. This leads to increased translocation of the catalytic subunit into the nucleus and altered gene expression. Introduction of a mutation decreasing RIβ:C dissociation controlled catalytic subunit translocation.","method":"Circular dichroism spectroscopy, structural analysis, direct measurements with purified proteins, patient-derived cell cultures, nuclear translocation assays","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1-2 — purified protein biochemistry, structural analysis, and cell-based assays with multiple orthogonal methods in a single study","pmids":["40244081"],"is_preprint":false},{"year":2021,"finding":"The PRKAR1B p.R115K variant causes stronger interaction between the R1β mutant and PKA catalytic subunit Cα, and decreased basal PKA activity compared to wildtype. Structural analysis suggests p.R115K may hinder conformational changes resulting from cAMP binding at cAMP binding domain A.","method":"FRET assay and PKA enzymatic assay in HEK293 cells; in silico structural analysis","journal":"Journal of the Endocrine Society","confidence":"Medium","confidence_rationale":"Tier 2-3 — two functional assays (FRET and enzymatic), single lab, structural prediction is computational","pmids":["34195525"],"is_preprint":false},{"year":2012,"finding":"The mouse Prkar1b gene produces three alternative splice variants (mR1β1, mR1β2, mR1β3) with different N-terminal protein structures, identified by RT-PCR and sequencing. Different N-termini in isoforms may be important for unique docking interactions with A-kinase anchoring proteins.","method":"RT-PCR, semi-nested PCR, sequencing, in silico analysis","journal":"Gene","confidence":"Low","confidence_rationale":"Tier 3 — molecular biology identification of splice variants; AKAP docking inference is not directly tested","pmids":["22446042"],"is_preprint":false}],"current_model":"PRKAR1B encodes the R1β regulatory subunit of PKA, which forms a homodimer that assembles with two catalytic subunits into the PKA holoenzyme; disease-associated mutations (notably L50R) disrupt R1β homodimerization causing monomer aggregation that is accelerated by cAMP and partially protected by catalytic subunit binding, while other variants (e.g., A67V, A300T, R335W, R115K) alter the affinity of R1β for the catalytic subunit and reduce basal PKA activity, with loss of proper holoenzyme assembly also impairing AKAP anchoring and causing aberrant nuclear translocation of the catalytic subunit and hyperphosphorylation of neuronal intermediate filaments."},"narrative":{"teleology":[{"year":2012,"claim":"Alternative splicing of Prkar1b generates N-terminally distinct RIβ isoforms, raising the question of whether different isoforms engage distinct AKAP partners and thus diversify subcellular PKA signaling.","evidence":"RT-PCR and sequencing of mouse brain cDNA identified three splice variants with different N-terminal domains","pmids":["22446042"],"confidence":"Low","gaps":["AKAP-docking specificity of individual isoforms is inferred computationally but not tested biochemically","Tissue-specific expression levels of each isoform are not quantified","Functional relevance of each isoform in vivo is unknown"]},{"year":2014,"claim":"The first disease-linked PRKAR1B mutation (L50R) demonstrated that RIβ is essential for proper AKAP anchoring and catalytic subunit localization in neurons, and that its disruption causes intermediate filament hyperphosphorylation and neuronal inclusion pathology.","evidence":"Exome sequencing of affected families, proteomics and biochemical binding assays, and immunohistochemistry of post-mortem brain tissue","pmids":["24722252"],"confidence":"Medium","gaps":["Binding defects were inferred from co-immunoprecipitation without reconstituted purified proteins","Whether intermediate filament hyperphosphorylation is directly catalyzed by mislocalized C subunit was not shown","No animal model was available at this stage"]},{"year":2020,"claim":"Identification of A67V and A300T variants revealed a second pathogenic mode — increased RIβ–Cα affinity with suppressed basal PKA activity — showing that both loosened and tightened regulatory-catalytic interactions are pathogenic.","evidence":"FRET-based interaction assay and PKA enzymatic activity measurement in co-transfected HEK293 cells; copy-number analysis in adrenal adenomas","pmids":["32895490"],"confidence":"Medium","gaps":["FRET measurements were performed in a single cell system without purified-protein confirmation","Downstream phosphorylation substrates affected by reduced basal PKA activity not identified","Whether adrenal copy-number gains act through the same biochemical mechanism as missense variants is unresolved"]},{"year":2021,"claim":"The R335W and R115K variants expanded the allelic series and confirmed that diverse PRKAR1B missense mutations converge on dysregulated PKA activity, firmly establishing PRKAR1B as a neurodevelopmental disease gene.","evidence":"PKA activity assays and FRET in transfected cells for R335W; FRET and enzymatic assays plus structural modeling for R115K","pmids":["33833410","34195525"],"confidence":"Medium","gaps":["Structural basis for altered cAMP-binding cooperativity at domain A (R115K) relies on in silico prediction","Neurodevelopmental phenotype mechanism not dissected at the cellular level","No in vivo model for these specific variants"]},{"year":2024,"claim":"A knock-in mouse model and human tissue studies established the molecular mechanism of L50R pathology: the mutation disrupts RIβ homodimerization, generating monomers that aggregate in a cAMP-accelerated and age-dependent manner, with catalytic subunit binding providing dose-dependent protection against aggregation.","evidence":"Biochemical dimerization and aggregation assays, Prkar1b-L50R knock-in mouse behavioral and histological analysis, human post-mortem brain immunohistochemistry, live cell culture experiments","pmids":["38743596"],"confidence":"High","gaps":["Whether pharmacological enhancement of C-subunit binding can prevent aggregation therapeutically is untested","Whether non-L50R dimerization-domain mutations share the same aggregation mechanism is unknown"]},{"year":2025,"claim":"Purified-protein biophysics revealed that L50R causes RIβ misfolding (not just dissociation), that the L50R:C heterodimer retains high affinity but loses cooperativity — requiring less cAMP for dissociation — and that the freed catalytic subunit translocates to the nucleus and alters gene expression, directly linking holoenzyme instability to transcriptional dysregulation.","evidence":"Circular dichroism spectroscopy and purified protein measurements; nuclear translocation assays in patient-derived cells; rescue by an engineered mutation reducing RIβ:C dissociation","pmids":["40244081"],"confidence":"High","gaps":["Specific nuclear substrates and gene expression changes downstream of aberrant C-subunit translocation not catalogued","Structural basis of reduced cooperativity at atomic resolution not resolved","Whether reduced cooperativity is a general feature of other pathogenic RIβ variants is unknown"]},{"year":null,"claim":"Key unresolved questions include the identity of nuclear PKA substrates and transcriptional programs altered by mislocalized catalytic subunit, the structural basis for how different mutations produce opposing effects on RIβ–C affinity, and whether therapeutic stabilization of the RIβ homodimer or holoenzyme can prevent neuronal aggregation and disease.","evidence":"","pmids":[],"confidence":"Low","gaps":["No phosphoproteomics of nuclear targets downstream of aberrant C-subunit translocation","No high-resolution structure of full-length RIβ holoenzyme with or without disease mutations","Therapeutic strategies targeting holoenzyme stability are unexplored"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2,3,4,5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,3,4,5]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,3,4]}],"complexes":["PKA type I holoenzyme"],"partners":["PRKACA","AKAP"],"other_free_text":[]},"mechanistic_narrative":"PRKAR1B encodes the RIβ regulatory subunit of cAMP-dependent protein kinase (PKA), which homodimerizes and assembles with two catalytic (C) subunits to form the type I PKA holoenzyme, serving as a key mediator of cAMP-dependent signaling in neurons. Disease-associated missense variants exert two distinct pathogenic mechanisms: mutations such as L50R disrupt RIβ homodimerization, producing misfolded monomers that aggregate in an age- and cAMP-dependent manner, prevent holoenzyme assembly and AKAP anchoring, and cause aberrant nuclear translocation of the catalytic subunit with consequent hyperphosphorylation of neuronal intermediate filaments and altered gene expression [PMID:24722252, PMID:38743596, PMID:40244081], whereas variants such as A67V, A300T, R115K, and R335W increase RIβ–Cα binding affinity and reduce basal PKA activity, establishing that both gain and loss of RIβ–C interaction dysregulate PKA signaling [PMID:32895490, PMID:33833410, PMID:34195525]. Mutations in PRKAR1B cause a neurodegenerative disorder characterized by neuronal RIβ-positive inclusions and a neurodevelopmental syndrome, linking disrupted PKA holoenzyme regulation directly to human neurological disease [PMID:24722252, PMID:33833410]."},"prefetch_data":{"uniprot":{"accession":"P31321","full_name":"cAMP-dependent protein kinase type I-beta regulatory subunit","aliases":[],"length_aa":381,"mass_kda":43.1,"function":"Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P31321/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRKAR1B","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PRKACA","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PRKAR1B","total_profiled":1310},"omim":[{"mim_id":"619680","title":"MARBACH-SCHAAF NEURODEVELOPMENTAL SYNDROME; MASNS","url":"https://www.omim.org/entry/619680"},{"mim_id":"612193","title":"CARDIOMYOPATHY-ASSOCIATED PROTEIN 5; CMYA5","url":"https://www.omim.org/entry/612193"},{"mim_id":"601639","title":"PROTEIN KINASE, cAMP-DEPENDENT, CATALYTIC, ALPHA; PRKACA","url":"https://www.omim.org/entry/601639"},{"mim_id":"176911","title":"PROTEIN KINASE, cAMP-DEPENDENT, REGULATORY, TYPE I, BETA; PRKAR1B","url":"https://www.omim.org/entry/176911"},{"mim_id":"176910","title":"PROTEIN KINASE, cAMP-DEPENDENT, REGULATORY, TYPE II, ALPHA; PRKAR2A","url":"https://www.omim.org/entry/176910"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":319.6}],"url":"https://www.proteinatlas.org/search/PRKAR1B"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P31321","domains":[{"cath_id":"2.60.120.10","chopping":"108-235","consensus_level":"high","plddt":93.7975,"start":108,"end":235},{"cath_id":"2.60.120.10","chopping":"254-381","consensus_level":"high","plddt":90.6763,"start":254,"end":381}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P31321","model_url":"https://alphafold.ebi.ac.uk/files/AF-P31321-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P31321-F1-predicted_aligned_error_v6.png","plddt_mean":86.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRKAR1B","jax_strain_url":"https://www.jax.org/strain/search?query=PRKAR1B"},"sequence":{"accession":"P31321","fasta_url":"https://rest.uniprot.org/uniprotkb/P31321.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P31321/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P31321"}},"corpus_meta":[{"pmid":"24722252","id":"PMC_24722252","title":"PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology.","date":"2014","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24722252","citation_count":54,"is_preprint":false},{"pmid":"34716310","id":"PMC_34716310","title":"EIF4A3-induced circular RNA PRKAR1B promotes osteosarcoma progression by miR-361-3p-mediated induction of FZD4 expression.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34716310","citation_count":35,"is_preprint":false},{"pmid":"33833410","id":"PMC_33833410","title":"Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain.","date":"2021","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33833410","citation_count":23,"is_preprint":false},{"pmid":"34513297","id":"PMC_34513297","title":"E2F3 promotes liver cancer progression under the regulation of circ-PRKAR1B.","date":"2021","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/34513297","citation_count":20,"is_preprint":false},{"pmid":"33668685","id":"PMC_33668685","title":"PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33668685","citation_count":17,"is_preprint":false},{"pmid":"32895490","id":"PMC_32895490","title":"Genomic and sequence variants of protein kinase A regulatory subunit type 1β (PRKAR1B) in patients with adrenocortical disease and Cushing syndrome.","date":"2020","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32895490","citation_count":15,"is_preprint":false},{"pmid":"29523662","id":"PMC_29523662","title":"A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy.","date":"2018","source":"Journal of the National Comprehensive Cancer Network : JNCCN","url":"https://pubmed.ncbi.nlm.nih.gov/29523662","citation_count":14,"is_preprint":false},{"pmid":"25108559","id":"PMC_25108559","title":"Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort.","date":"2014","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25108559","citation_count":13,"is_preprint":false},{"pmid":"15579186","id":"PMC_15579186","title":"Genomic structure of the human gene for protein kinase A regulatory subunit R1-beta (PRKAR1B) on 7p22: no evidence for mutations in familial hyperaldosteronism type II in a large affected kindred.","date":"2004","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15579186","citation_count":13,"is_preprint":false},{"pmid":"38743596","id":"PMC_38743596","title":"A mutation in the PRKAR1B gene drives pathological mechanisms of neurodegeneration across species.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38743596","citation_count":6,"is_preprint":false},{"pmid":"40244081","id":"PMC_40244081","title":"Allosteric modulation of protein kinase A in individuals affected by NLPD-PKA, a neurodegenerative disease in which the PRKAR1B L50R variant is expressed.","date":"2025","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/40244081","citation_count":5,"is_preprint":false},{"pmid":"34195525","id":"PMC_34195525","title":"The PRKAR1B p.R115K Variant is Associated with Lipoprotein Profile in African American Youth with Metabolic Challenges.","date":"2021","source":"Journal of the Endocrine Society","url":"https://pubmed.ncbi.nlm.nih.gov/34195525","citation_count":5,"is_preprint":false},{"pmid":"22446042","id":"PMC_22446042","title":"Two novel N-terminal coding exons of Prkar1b gene of mouse: identified using a novel approach of in silico and molecular biology techniques.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22446042","citation_count":3,"is_preprint":false},{"pmid":"41163438","id":"PMC_41163438","title":"Expansion of the Phenotypic and Genotypic Spectrum for PRKAR1B -Related Marbach-Schaaf Neurodevelopmental Syndrome: A Case Series.","date":"2025","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41163438","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8573,"output_tokens":1837,"usd":0.026637},"stage2":{"model":"claude-opus-4-6","input_tokens":5167,"output_tokens":2163,"usd":0.119865},"total_usd":0.146502,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"The PRKAR1B p.Leu50Arg (L50R) missense mutation causes reduced binding of the R1β regulatory subunit to both A-kinase anchoring proteins (AKAPs) and the catalytic subunit of PKA, leading to subcellular dislocalization of the catalytic subunit and hyperphosphorylation of intermediate filaments. Mutant PRKAR1B accumulates specifically in neuronal inclusions.\",\n      \"method\": \"Proteomics, biochemical assay, linkage analysis/exome sequencing, immunohistochemistry of patient brain tissue\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — patient tissue proteomics and biochemical pattern, single lab, no in vitro reconstitution of binding\",\n      \"pmids\": [\"24722252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"De novo missense variants in PRKAR1B (including p.Arg335Trp) alter basal PKA activity in transfected cells, establishing that PRKAR1B variants cause a neurodevelopmental disorder through dysregulated PKA signaling.\",\n      \"method\": \"In vitro PKA activity assay in cells transfected with variant-harboring PRKAR1B expression constructs; exome sequencing for variant identification\",\n      \"journal\": \"Genetics in medicine : official journal of the American College of Medical Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro functional assay with multiple variants, single lab\",\n      \"pmids\": [\"33833410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRKAR1B variants p.A67V and p.A300T decrease basal PKA activity in vitro, and the mutant R1β subunits bind the PKA catalytic subunit Cα more strongly than wildtype as measured by FRET in co-transfected HEK293 cells. Copy-number gains of PRKAR1B in cortisol-producing adrenal adenomas are associated with increased PRKAR1B mRNA and reduced PKA activity.\",\n      \"method\": \"In vitro PKA activity assay; FRET in co-transfected HEK293 cells; copy-number variant analysis with mRNA quantification\",\n      \"journal\": \"Genetics in medicine : official journal of the American College of Medical Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — FRET and enzymatic assay, two orthogonal methods, single lab\",\n      \"pmids\": [\"32895490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The RIβ-L50R mutation disrupts RIβ homodimerization, causing aggregation of RIβ monomers in an age-dependent manner. Interaction with the catalytic subunit protects RIβ-L50R from self-aggregation in a dose-dependent manner. cAMP signaling induces RIβ-L50R aggregation. These mechanisms were demonstrated in a knock-in mouse model, live cell cultures, and post-mortem human brains.\",\n      \"method\": \"Biochemical assays (dimerization, aggregation), immunohistochemistry, behavioral assessments in knock-in mouse model, cell culture experiments\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (biochemical, in vivo mouse model, human tissue), mechanistic dissection of dimerization and aggregation\",\n      \"pmids\": [\"38743596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Structural analysis and circular dichroism spectroscopy showed that cellular protein aggregation of RIβ-L50R results from misfolded RIβ subunits that prevent holoenzyme assembly and AKAP anchoring. The RIβ-L50R:C heterodimer maintains high affinity to the catalytic subunit but exhibits reduced cooperativity, requiring lower cAMP concentrations for dissociation. This leads to increased translocation of the catalytic subunit into the nucleus and altered gene expression. Introduction of a mutation decreasing RIβ:C dissociation controlled catalytic subunit translocation.\",\n      \"method\": \"Circular dichroism spectroscopy, structural analysis, direct measurements with purified proteins, patient-derived cell cultures, nuclear translocation assays\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — purified protein biochemistry, structural analysis, and cell-based assays with multiple orthogonal methods in a single study\",\n      \"pmids\": [\"40244081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The PRKAR1B p.R115K variant causes stronger interaction between the R1β mutant and PKA catalytic subunit Cα, and decreased basal PKA activity compared to wildtype. Structural analysis suggests p.R115K may hinder conformational changes resulting from cAMP binding at cAMP binding domain A.\",\n      \"method\": \"FRET assay and PKA enzymatic assay in HEK293 cells; in silico structural analysis\",\n      \"journal\": \"Journal of the Endocrine Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — two functional assays (FRET and enzymatic), single lab, structural prediction is computational\",\n      \"pmids\": [\"34195525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The mouse Prkar1b gene produces three alternative splice variants (mR1β1, mR1β2, mR1β3) with different N-terminal protein structures, identified by RT-PCR and sequencing. Different N-termini in isoforms may be important for unique docking interactions with A-kinase anchoring proteins.\",\n      \"method\": \"RT-PCR, semi-nested PCR, sequencing, in silico analysis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — molecular biology identification of splice variants; AKAP docking inference is not directly tested\",\n      \"pmids\": [\"22446042\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRKAR1B encodes the R1β regulatory subunit of PKA, which forms a homodimer that assembles with two catalytic subunits into the PKA holoenzyme; disease-associated mutations (notably L50R) disrupt R1β homodimerization causing monomer aggregation that is accelerated by cAMP and partially protected by catalytic subunit binding, while other variants (e.g., A67V, A300T, R335W, R115K) alter the affinity of R1β for the catalytic subunit and reduce basal PKA activity, with loss of proper holoenzyme assembly also impairing AKAP anchoring and causing aberrant nuclear translocation of the catalytic subunit and hyperphosphorylation of neuronal intermediate filaments.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRKAR1B encodes the RIβ regulatory subunit of cAMP-dependent protein kinase (PKA), which homodimerizes and assembles with two catalytic (C) subunits to form the type I PKA holoenzyme, serving as a key mediator of cAMP-dependent signaling in neurons. Disease-associated missense variants exert two distinct pathogenic mechanisms: mutations such as L50R disrupt RIβ homodimerization, producing misfolded monomers that aggregate in an age- and cAMP-dependent manner, prevent holoenzyme assembly and AKAP anchoring, and cause aberrant nuclear translocation of the catalytic subunit with consequent hyperphosphorylation of neuronal intermediate filaments and altered gene expression [PMID:24722252, PMID:38743596, PMID:40244081], whereas variants such as A67V, A300T, R115K, and R335W increase RIβ–Cα binding affinity and reduce basal PKA activity, establishing that both gain and loss of RIβ–C interaction dysregulate PKA signaling [PMID:32895490, PMID:33833410, PMID:34195525]. Mutations in PRKAR1B cause a neurodegenerative disorder characterized by neuronal RIβ-positive inclusions and a neurodevelopmental syndrome, linking disrupted PKA holoenzyme regulation directly to human neurological disease [PMID:24722252, PMID:33833410].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Alternative splicing of Prkar1b generates N-terminally distinct RIβ isoforms, raising the question of whether different isoforms engage distinct AKAP partners and thus diversify subcellular PKA signaling.\",\n      \"evidence\": \"RT-PCR and sequencing of mouse brain cDNA identified three splice variants with different N-terminal domains\",\n      \"pmids\": [\"22446042\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"AKAP-docking specificity of individual isoforms is inferred computationally but not tested biochemically\",\n        \"Tissue-specific expression levels of each isoform are not quantified\",\n        \"Functional relevance of each isoform in vivo is unknown\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The first disease-linked PRKAR1B mutation (L50R) demonstrated that RIβ is essential for proper AKAP anchoring and catalytic subunit localization in neurons, and that its disruption causes intermediate filament hyperphosphorylation and neuronal inclusion pathology.\",\n      \"evidence\": \"Exome sequencing of affected families, proteomics and biochemical binding assays, and immunohistochemistry of post-mortem brain tissue\",\n      \"pmids\": [\"24722252\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Binding defects were inferred from co-immunoprecipitation without reconstituted purified proteins\",\n        \"Whether intermediate filament hyperphosphorylation is directly catalyzed by mislocalized C subunit was not shown\",\n        \"No animal model was available at this stage\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of A67V and A300T variants revealed a second pathogenic mode — increased RIβ–Cα affinity with suppressed basal PKA activity — showing that both loosened and tightened regulatory-catalytic interactions are pathogenic.\",\n      \"evidence\": \"FRET-based interaction assay and PKA enzymatic activity measurement in co-transfected HEK293 cells; copy-number analysis in adrenal adenomas\",\n      \"pmids\": [\"32895490\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"FRET measurements were performed in a single cell system without purified-protein confirmation\",\n        \"Downstream phosphorylation substrates affected by reduced basal PKA activity not identified\",\n        \"Whether adrenal copy-number gains act through the same biochemical mechanism as missense variants is unresolved\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The R335W and R115K variants expanded the allelic series and confirmed that diverse PRKAR1B missense mutations converge on dysregulated PKA activity, firmly establishing PRKAR1B as a neurodevelopmental disease gene.\",\n      \"evidence\": \"PKA activity assays and FRET in transfected cells for R335W; FRET and enzymatic assays plus structural modeling for R115K\",\n      \"pmids\": [\"33833410\", \"34195525\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Structural basis for altered cAMP-binding cooperativity at domain A (R115K) relies on in silico prediction\",\n        \"Neurodevelopmental phenotype mechanism not dissected at the cellular level\",\n        \"No in vivo model for these specific variants\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A knock-in mouse model and human tissue studies established the molecular mechanism of L50R pathology: the mutation disrupts RIβ homodimerization, generating monomers that aggregate in a cAMP-accelerated and age-dependent manner, with catalytic subunit binding providing dose-dependent protection against aggregation.\",\n      \"evidence\": \"Biochemical dimerization and aggregation assays, Prkar1b-L50R knock-in mouse behavioral and histological analysis, human post-mortem brain immunohistochemistry, live cell culture experiments\",\n      \"pmids\": [\"38743596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether pharmacological enhancement of C-subunit binding can prevent aggregation therapeutically is untested\",\n        \"Whether non-L50R dimerization-domain mutations share the same aggregation mechanism is unknown\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Purified-protein biophysics revealed that L50R causes RIβ misfolding (not just dissociation), that the L50R:C heterodimer retains high affinity but loses cooperativity — requiring less cAMP for dissociation — and that the freed catalytic subunit translocates to the nucleus and alters gene expression, directly linking holoenzyme instability to transcriptional dysregulation.\",\n      \"evidence\": \"Circular dichroism spectroscopy and purified protein measurements; nuclear translocation assays in patient-derived cells; rescue by an engineered mutation reducing RIβ:C dissociation\",\n      \"pmids\": [\"40244081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Specific nuclear substrates and gene expression changes downstream of aberrant C-subunit translocation not catalogued\",\n        \"Structural basis of reduced cooperativity at atomic resolution not resolved\",\n        \"Whether reduced cooperativity is a general feature of other pathogenic RIβ variants is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of nuclear PKA substrates and transcriptional programs altered by mislocalized catalytic subunit, the structural basis for how different mutations produce opposing effects on RIβ–C affinity, and whether therapeutic stabilization of the RIβ homodimer or holoenzyme can prevent neuronal aggregation and disease.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No phosphoproteomics of nuclear targets downstream of aberrant C-subunit translocation\",\n        \"No high-resolution structure of full-length RIβ holoenzyme with or without disease mutations\",\n        \"Therapeutic strategies targeting holoenzyme stability are unexplored\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 3, 4]}\n    ],\n    \"complexes\": [\n      \"PKA type I holoenzyme\"\n    ],\n    \"partners\": [\n      \"PRKACA\",\n      \"AKAP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}